April 24, 2020

Antiviral Therapeutics and Vaccines

  • Recovery Trial
    The Recovery Trial is a multi-arm multi-stage adaptive trial with mortality as the primary endpoint together with a 10 year follow up period linked to the electronic health records of ~6900 Covid-19 patients in the UK enrolled to date treated with either:  placebo or ritonavir/lopinavir or steroids or azithromycin or hydroxy-chloroquine. For patients whose clinical condition deteriorates, a second randomization occurs to either placebo or tocilizumab. This study will address the information gaps noted in the NIH Covid-19 treatment guidelines previously posted to Parasite without Borders.

Situation Dashboards

World_Health_Organization_logo_logotype

World Health Organization (WHO)

Novel Coronavirus (COVID-19) Situation from World Health Organization (WHO)
university-logo-small-horizontal-blue-no-clear-space-51c7fb4524

Johns Hopkins University (JHU)

Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at JHU
1point3acres

COVID-19 in US and Canada

1Point3Acres Real-Time Coronavirus (COVID-19) Updates in US and Canada with Credible Sources
image

Genomic Epidemiology COVID-19

Genomic Epidemiology of (COVID-19) Maintained by the Nextstrain team, enabled by data from GISAID.

Sources for COVID-19 Information

World_Health_Organization_logo_logotype

World Health Organization (WHO)

1280px-US_CDC_logo.svg

Centers for Disease Control, US

ProMED-Logo

International Society for Infectious Diseases

twiv-logo

This Week in Virology (TWIV)

Parasites Without Borders

A comprehensive educational resource on all aspects of parasitic diseases and their impact on humanity around the globe.

Donate to Parasites Without Borders today!

Help bring the latest medical and basic biological information pertaining to diseases caused by eukaryotic parasites to every practicing physician and medical student within the United States. 

Scroll to Top